


Data analysis and reporting for the TruSight[™] Oncology 500 portfolio

Integrated bioinformatics provide sample-to-insight workflows to enable solid tumor CGP

DRAGEN™ secondary analysis across the entire TruSight Oncology 500 portfolio reduces analysis time by 2-10×. Run DRAGEN TruSight Oncology 500 and DRAGEN TruSight Oncology 500 ctDNA Analysis Software, provided with each kit, locally with an on-premises DRAGEN server or in the cloud via Illumina Connected Analytics. Options for customized reporting and insights include Illumina Connected Insights and Velsera Clinical Genomics Workspace (CGW).



^{*} NextSeq 550Dx or NovaSeq 6000Dx Instruments in research mode only. † Requires separate, standalone DRAGEN server if local secondary analysis is desired. ‡ TruSight Oncology 500 High-Throughput is also compatible with the NextSeq 550 System and NextSeq 550Dx Instrument in research mode for up to eight samples. § NovaSeq 6000Dx Instrument in research mode has not been extensively tested, but is considered technically compatible. ** Not available in all countries. Illumina Connected Insights supports user-defined tertiary analysis through API calls to third-party knowledge sources.

Better variant calling with DRAGEN analysis



Accurate

- DRAGEN secondary analysis brings awardwinning accuracy to TruSight Oncology 500
- 99.83% accuracy score with the precisionFDA Truth Challenge V2^{1,2}



Comprehensive

- Comprehensive coverage of all variant classes: SNVs, indels, CNVs, MNVs, SVs; immuno-oncology and other gene signatures: TMB, MSI, and HRD (GIS)*
- New beta features[†] available with TruSight Oncology 500 HRD assay enable reporting of tumor fraction, ploidy, absolute copy numbers, and gene-level LOH



 DRAGEN secondary analysis completes 2-10× faster than other pipelines

		Third-party server ^a	DRAGEN Server v4
Assay	No. of samples ^b	Analysis time ^c	
TruSight Oncology 500 or TruSight Oncology 500 High- Throughput	8 tissue biopsy	5.5 hrs	2 hrs
	16 tissue biopsy	12 hrs	3 hrs
	32 tissue biopsy	18 hrs	7 hrs
	72 tissue biopsy	24 hrs	16 hrs
TruSight Oncology 500 ctDNA v2	24 liquid biopsy	216 hrs (9 days)	20 hrs (< 1 day)

- Third-party server: c5.9×large instance (36 vCPU, 72 GiB memory).
- Number of samples processed in a single batch per week. Approximate analysis times are based on actual runs, analysis times will vary.



Flexible

- Local and cloud-based analysis allow labs to choose an option that best suits their needs
- User interface designed for general users as well as bioinformatics professionals



Easy to use

- User-friendly interface to set up and configure analysis
- No manual touchpoints available with automated data transfer and analysis kickoff



Scalable

- · Cloud-based analysis enables scaling without additional hardware investment
- Reducing manual touchpoints with automation allows scalability without adding headcount

Drive more genomic insights with the TruSight Oncology 500 portfolio and **DRAGEN** analysis:



TruSight Oncology 500 with DRAGEN analysis



DRAGEN secondary analysis

- * HRD (GIS) is for tissue workflows only (not available with TruSight Oncology 500 ctDNA).
- † Beta features have not been verified by Illumina. See customer release notes for v2.5+ for more details.

SNV, single nucleotide variant; indel, insertions and deletions; CNV, copy number variant; MNV, multinucleotide variant; SV, structural variant; TMB, tumor mutational burden; MSI, microsatellite instability; GIS, genomic instability; LOH, loss of heterozygosity

References

- Food and Drug Administration. Truth Challenge V2: Calling Variants from Short and Long Reads in Difficult-to-Map Regions, precision, fda.gov/challenges/10. Accessed March 14, 2022.
- Illumina. DRAGEN Sets New Standard for Data Accuracy in PrecisionFDA Benchmark Data. Optimizing Variant Calling Performance with Illumina Machine Learning and DRAGEN Graph. illumina.com/science/genomics-research/articles/dragen-shines-again-precisionfda-truth-challenge-v2.html. Accessed March 14, 2022.

